HRP20050075B1 - Primjena specifiäśnog derivata cikliäśkog amina ili njegovih farmaceutski prihvatljivih soli u lijeäśenju ili prevenciji zatajenja srca - Google Patents

Primjena specifiäśnog derivata cikliäśkog amina ili njegovih farmaceutski prihvatljivih soli u lijeäśenju ili prevenciji zatajenja srca

Info

Publication number
HRP20050075B1
HRP20050075B1 HRP20050075AA HRP20050075A HRP20050075B1 HR P20050075 B1 HRP20050075 B1 HR P20050075B1 HR P20050075A A HRP20050075A A HR P20050075AA HR P20050075 A HRP20050075 A HR P20050075A HR P20050075 B1 HRP20050075 B1 HR P20050075B1
Authority
HR
Croatia
Prior art keywords
prevention
treatment
pharmaceutically acceptable
acceptable salts
heart failure
Prior art date
Application number
HRP20050075AA
Other languages
English (en)
Croatian (hr)
Inventor
Brian Guth
Randolph Seidler
Juergen Daemmgen
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050075(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20050075A2 publication Critical patent/HRP20050075A2/xx
Publication of HRP20050075B1 publication Critical patent/HRP20050075B1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20050075AA 2002-07-25 2003-07-21 Primjena specifiäśnog derivata cikliäśkog amina ili njegovih farmaceutski prihvatljivih soli u lijeäśenju ili prevenciji zatajenja srca HRP20050075B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
PCT/EP2003/007929 WO2004011006A1 (en) 2002-07-25 2003-07-21 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (2)

Publication Number Publication Date
HRP20050075A2 HRP20050075A2 (en) 2005-12-31
HRP20050075B1 true HRP20050075B1 (hr) 2013-12-20

Family

ID=29265956

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050075AA HRP20050075B1 (hr) 2002-07-25 2003-07-21 Primjena specifiäśnog derivata cikliäśkog amina ili njegovih farmaceutski prihvatljivih soli u lijeäśenju ili prevenciji zatajenja srca

Country Status (29)

Country Link
US (1) US20130317008A1 (enExample)
EP (2) EP1362590B1 (enExample)
JP (3) JP2005533853A (enExample)
KR (1) KR20050074432A (enExample)
CN (1) CN100502874C (enExample)
AR (1) AR040690A1 (enExample)
AT (2) ATE257384T1 (enExample)
AU (1) AU2003254554B8 (enExample)
BR (1) BR0312852A (enExample)
CA (1) CA2493208C (enExample)
CO (1) CO5700723A2 (enExample)
CY (1) CY1112173T1 (enExample)
DE (1) DE60200160T2 (enExample)
DK (2) DK1362590T3 (enExample)
ES (2) ES2211846T3 (enExample)
HR (1) HRP20050075B1 (enExample)
MX (1) MXPA05000617A (enExample)
MY (1) MY128529A (enExample)
NZ (1) NZ538424A (enExample)
PE (1) PE20040706A1 (enExample)
PL (1) PL214716B1 (enExample)
PT (2) PT1362590E (enExample)
SA (1) SA03240350B1 (enExample)
SI (2) SI1362590T1 (enExample)
TR (1) TR200400127T4 (enExample)
TW (1) TWI319321B (enExample)
UY (1) UY27910A1 (enExample)
WO (1) WO2004011006A1 (enExample)
ZA (1) ZA200500084B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257384T1 (de) * 2002-07-25 2004-01-15 Boehringer Ingelheim Pharma Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
WO2007023775A1 (ja) * 2005-08-23 2007-03-01 Astellas Pharma Inc. 心房細動治療剤
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR20140057604A (ko) * 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
EP2953612A1 (en) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit-of-parts

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224794A2 (de) * 1985-11-27 1987-06-10 Dr. Karl Thomae GmbH Neue cyclische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0330052A2 (de) * 1988-02-24 1989-08-30 Dr. Karl Thomae GmbH Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica
EP0471388A2 (de) * 1987-10-30 1992-02-19 Dr. Karl Thomae GmbH Mittel zur Behandlung der Herzinsuffizienz
WO2001078699A2 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Kg Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
PT1186601E (pt) * 1999-06-03 2004-06-30 Yamanouchi Pharma Co Ltd Novos derivados de isoquinolina ou seus sais
ATE257384T1 (de) * 2002-07-25 2004-01-15 Boehringer Ingelheim Pharma Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224794A2 (de) * 1985-11-27 1987-06-10 Dr. Karl Thomae GmbH Neue cyclische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0471388A2 (de) * 1987-10-30 1992-02-19 Dr. Karl Thomae GmbH Mittel zur Behandlung der Herzinsuffizienz
EP0330052A2 (de) * 1988-02-24 1989-08-30 Dr. Karl Thomae GmbH Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica
WO2001078699A2 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Kg Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Also Published As

Publication number Publication date
TR200400127T4 (tr) 2004-02-23
JP2009256379A (ja) 2009-11-05
KR20050074432A (ko) 2005-07-18
JP2013166781A (ja) 2013-08-29
MY128529A (en) 2007-02-28
ES2367109T3 (es) 2011-10-28
SA03240350B1 (ar) 2007-10-29
ZA200500084B (en) 2005-10-26
DK1534296T3 (da) 2011-08-15
PL214716B1 (pl) 2013-09-30
DE60200160T2 (de) 2004-11-04
CA2493208C (en) 2011-11-01
PT1534296E (pt) 2011-08-18
TW200412974A (en) 2004-08-01
MXPA05000617A (es) 2005-08-19
US20130317008A1 (en) 2013-11-28
AU2003254554B2 (en) 2009-01-29
EP1534296A1 (en) 2005-06-01
AU2003254554B8 (en) 2009-02-26
PT1362590E (pt) 2004-05-31
CO5700723A2 (es) 2006-11-30
EP1362590B1 (en) 2004-01-07
SI1362590T1 (sl) 2004-04-30
ATE510543T1 (de) 2011-06-15
UY27910A1 (es) 2004-02-27
AU2003254554A1 (en) 2004-02-16
CY1112173T1 (el) 2015-12-09
ES2211846T3 (es) 2004-07-16
WO2004011006A1 (en) 2004-02-05
NZ538424A (en) 2006-10-27
JP2005533853A (ja) 2005-11-10
AR040690A1 (es) 2005-04-13
TWI319321B (en) 2010-01-11
BR0312852A (pt) 2005-04-19
DE60200160D1 (de) 2004-02-12
PE20040706A1 (es) 2004-12-06
EP1362590A1 (en) 2003-11-19
DK1362590T3 (da) 2004-03-29
PL372993A1 (en) 2005-08-08
ATE257384T1 (de) 2004-01-15
CA2493208A1 (en) 2004-02-05
EP1362590A8 (en) 2004-02-25
HRP20050075A2 (en) 2005-12-31
CN100502874C (zh) 2009-06-24
CN1671392A (zh) 2005-09-21
SI1534296T1 (sl) 2011-09-30
EP1534296B1 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
IS6902A (is) N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl
ATE440603T1 (de) 8-hydroxychinolinderivate
HRP20040996B1 (hr) Tablete visokog sadržaja lijeka
BR0109703A (pt) Derivados de piperazina
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
MEP15908A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
CY1112173T1 (el) Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας
ATE308522T1 (de) Opioidrezeptorantagonisten
MEP13608A (en) 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
NO20052907L (no) Sykloalkylendikarboksylsyreforbindelser som antiinflammatoriske, immunmodulatoriske og antiproliferative midler
BR0210912A (pt) Compostos e composições como inibidores de catepsina
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
HRP20050055B1 (hr) Mikrokapsule za odloženo i kontrolirano oslobađanje perindoprila
ECSP034708A (es) Nueva sal de benzoilguanidina
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
WO2007039909A3 (en) Compositions and methods for treatment of renal failure

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20150706

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20160721